ARTV — Artiva Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Artiva Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -71.8 | -58.8 | -28.7 | -65.4 | -83.9 |
| Depreciation | |||||
| Non-Cash Items | 22.9 | 10.7 | 7.3 | 8.23 | 4.94 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 33.4 | -3.87 | -28.3 | -0.325 | -0.424 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.3 | -50.8 | -47.4 | -55 | -76.8 |
| Capital Expenditures | -1.72 | -6.3 | -3.26 | -0.642 | -2.59 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0 | -22.7 | -120 | 66 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.72 | -6.3 | -26 | -120 | 63.4 |
| Financing Cash Flow Items | -2.03 | -1.59 | 24.4 | -4.18 | -0.23 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 153 | -1.26 | 24.4 | 162 | 0.009 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 136 | -58.4 | -49 | -13.3 | -13.3 |